BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value Health Reg Issues 2021;24:82-9. [PMID: 33524900 DOI: 10.1016/j.vhri.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou T, Wang X, Cao Y, Yang L, Wang Z, Ma A, Li H. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res 2022;22:1367. [DOI: 10.1186/s12913-022-08661-4] [Reference Citation Analysis]
2 Zhao M, Pan X, Yin Y, Hu H, Wei J, Bai Z, Tang W. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Front Public Health 2022;10:869960. [DOI: 10.3389/fpubh.2022.869960] [Reference Citation Analysis]
3 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]